Measuring the CD180 protein on blood cells in acute myeloid leukemia
Studies CD180 levels on leukemia cells and healthy blood stem cells.
Plain-language title generated from the registry record
Registry title: Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
Key facts
- Where
- Strasbourg, FranceSee the site
Where in France
- Laboratoire d'Hématologie Biologique - CHU de Strasbourg - FranceStrasbourg, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT07895901
- Record updated
- 26 October 2026
- Original description
CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies. It may have diagnostic and monitoring potential, particularly in acute myeloid leukemia (AML).Read full original descriptionShow less
Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies. It may have diagnostic and monitoring potential, particularly in acute myeloid leukemia (AML).
This monocentric, non-interventional, retrospective observational study aims to characterize CD180 expression by flow cytometry in pathological hematopoietic cells, particularly in AML, and in normal hematopoietic stem and progenitor cells (CD34+ cells). The study will use residual blood and bone marrow samples collected during routine care and otherwise intended for disposal by incineration, together with relevant clinical and laboratory data.
Inclusion: Adult patients aged 18 years or older; Pediatric patients aged 1 to 17 years; Patients with confirmed or suspected acute myeloid leukemia who have undergone bone marrow aspiration as part of the diagnostic or relapse assessment; Patients whose stem cells are being assessed using a blood or bone marrow sample; Patients and/or their legal representatives, where applicable, informed by letter of the use of residual sample material for research purposes; No written objection documented in the medical record to the reuse of personal data for scientific research.
Exclusion: Patients and/or their legal representatives, where applicable, who have objected to the reuse of personal data for scientific research; Samples more than 72 hours old; Clotted samples; Samples with insufficient volume (less than 10 microliters).